Breaking News

Financial Report: Baxalta

February 17, 2016

Revenues up 5% in the quarter

4Q Revenues: $1.8 billion (+5%)
4Q Earnings: $95 million (earnings were $763 million 4Q14)
FY Revenues: $6.1 billion (+3%)
FY Earnings: $956 million (-47%)
Hematology revenues were $1.0 billion in the quarter, down 2%. Immunology revenues were $680 million, up 8%. Oncology revenues were $53 million from the acquisition of ONCASPAR (pegaspargase) leukemia portfolio from Sigma-Tau. Results include after-tax special items totaling $292 million, primarily for asset repayment, expenses associated with the company’s separation from Baxter International, and certain business development and collaboration-related items.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus